ResearchLp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C: A Mendelian Randomization Study
ResearchObesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER
ResearchAbstract 4369532: Estimated absolute coronary heart disease risk reduction with Lp(a) lowering among adults with atherosclerotic cardiovascular disease
ResearchHeterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US
ResearchIntraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial
ResearchOlpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study
ResearchOlpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial
ResearchCardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial
ResearchAssociation of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos
ResearchLipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease
Mar 28, 2024Journal ArticleEvolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.Written by 1 Roon author & 10 others Via The American Heart Association Journals
ResearchAssociation Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE